Impact of nitroglycerin and verapamil on coronary arterial distensibility as assessed by intravascular ultrasound

J Invasive Cardiol. 2009 Apr;21(4):162-7.

Abstract

Objectives: To examine the effects of coronary artery vasodilators on coronary arterial distensibility using intravascular coronary ultrasound (IVUS).

Background: There is limited information on the effect of coronary artery vasodilators on coronary arterial distensibility.

Methods: We studied 20 patients using IVUS. Patients received 100 microg of nitroglycerin (10 patients) or 1 mg of verapamil (10 patients) intravenously. We measured coronary arterial elasticity, the distensibility index, compliance and stiffness index. There were no differences in patient characteristics, lesion characteristics or baseline coronary arterial distensibility between the two groups.

Results: Systolic and diastolic blood pressure decreased in both groups (p < 0.05). Maximal coronary arterial cross-sectional luminal area (LA) during the cardiac cycle showed similar dilation in both groups. Nitroglycerin increased maximal LA by 5%, and verapamil increased it by 4% (p < 0.05; p < 0.0001, respectively). However, the degree of dilation of the minimal LA during the cardiac cycle showed a different pattern. Nitroglycerin dilated the minimal LA by 8%, while verapamil dilated the minimal LA by 2% (p < 0.001, p < 0.05, respectively). Consequently, the degree of expansion of LA during each cardiac cycle increased in the verapamil group and decreased in the nitroglycerin group. Thus, nitroglycerin decreased elasticity by 31% (p < 0.001), with no change in compliance, stiffness index or distensibility index. While, verapamil increased elasticity by 37%, the distensibility index by 48% and compliance by 53%, and decreased the stiffness index by 27% (all, p < 0.0001).

Conclusions: While both drugs acutely dilate the coronary arteries, nitroglycerin reduced local coronary arterial distensibility; however, verapamil increased local coronary arterial distensibility.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Analysis of Variance
  • Calcium Channel Blockers / pharmacology*
  • Calcium Channel Blockers / therapeutic use
  • Compliance / drug effects
  • Coronary Angiography
  • Diastole / drug effects
  • Elasticity / drug effects
  • Health Status Indicators
  • Hemodynamics / drug effects
  • Humans
  • Nitroglycerin / pharmacology*
  • Nitroglycerin / therapeutic use
  • Systole / drug effects
  • Ultrasonography, Interventional*
  • Vasodilator Agents / pharmacology*
  • Vasodilator Agents / therapeutic use
  • Verapamil / pharmacology*
  • Verapamil / therapeutic use

Substances

  • Calcium Channel Blockers
  • Vasodilator Agents
  • Verapamil
  • Nitroglycerin